Greiner Bio-One GmbH
http://www.greinerbioone.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Greiner Bio-One GmbH
Medical Device Deals Update, March 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
Deals In Depth: January 2013
Gilead licensed rights to four preclinical antibodies from MacroGenics. Stryker bought Chinese device company Trauson for $751 million. Biopharma companies raised double the amount from December, bringing in $2.8 billion, while device funding dropped to $269 million.
Deals Shaping The Medical Industry, March 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
reinnervate Ltd.
reinnervate Ltd. is commercializing Alvetex, a three-dimensional scaffold for cell culture. By supporting cell cultures that are more representative of the original tissues, Alvetex cultures could help drug companies fail drugs at an earlier stage, and could reduce the numbers of animals required in testing, thereby saving money in drug development.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice